RAD52-2 Antibody

What is RAD52 and why is it significant in DNA repair research?

RAD52 is a key member of the homologous recombination (HR) pathway critical for DNA double-strand break (DSB) repair. It was originally identified in Saccharomyces cerevisiae during genetic screening for mutants sensitive to ionizing radiation and was defined as part of the RAD52 epistasis group . RAD52's significance stems from its multiple roles in:

• Double-strand break repair

• Single-strand DNA annealing (SSA)

• Maintenance of genomic integrity

• Resolution of transcription-replication conflicts (TRCs)

• Alternative telomere length maintenance

• Synthetic lethality in BRCA-deficient cancer cells

In mammalian cells, RAD52 has emerged as a potential therapeutic target, particularly in BRCA-deficient cancers where RAD52 inhibition results in synthetic lethality .

What are the key functional domains of RAD52 that antibodies might target?

RAD52 contains distinct functional domains that antibodies may target for specific research applications:

When selecting antibodies, researchers should consider which domain they wish to target based on their experimental objectives .

What applications are RAD52 antibodies typically used for in research settings?

RAD52 antibodies are employed in diverse research applications:

• Western blotting (WB): Detection of RAD52 protein expression levels in cell lysates

• Immunoprecipitation (IP): Isolation of RAD52 and associated protein complexes

• Immunofluorescence (IF): Visualization of RAD52 foci formation after DNA damage

• Immunohistochemistry with paraffin-embedded sections (IHCP): Analysis of RAD52 expression in tissue samples

• Enzyme-linked immunosorbent assay (ELISA): Quantitative detection of RAD52 protein

• Proximity ligation assay (PLA): Investigation of RAD52 interactions with other proteins like RNA Pol II

• Chromatin immunoprecipitation (ChIP): Examination of RAD52 binding to specific genomic regions

For RAD52-2 antibodies specifically focusing on the Arabidopsis thaliana ortholog, these applications help investigate plant-specific DNA repair mechanisms .

How should I design experiments to study RAD52 foci formation after DNA damage?

When designing experiments to study RAD52 foci formation:

• Cell preparation:

  • Grow cells on coverslips to 60-70% confluence

  • For BRCA-deficient cells, consider MDA-MB-436, HCC1937 (BRCA1-/-), or CAPAN-1 (BRCA2-/-) cell lines

• DNA damage induction:

  • Use cisplatin (5 μM for 6 hours) for consistent DNA damage

  • Alternative agents: camptothecin (CPT), ionizing radiation, or hydroxyurea

• Immunostaining protocol:

  • Fix cells with 4% paraformaldehyde

  • Permeabilize with 0.2% Triton X-100

  • Block with 3-5% BSA

  • Incubate with RAD52 antibody (1:100-1:500 dilution)

  • Include γH2AX antibody as a DNA damage marker for co-localization studies

  • Use fluorescently labeled secondary antibodies

• Controls:

  • Include RAD52-knockout cells as negative controls

  • Use cells expressing HA-tagged RAD52 and stain with both RAD52 and HA antibodies to confirm specificity

• Analysis:

  • Quantify percentage of cells with RAD52 foci

  • Measure co-localization with γH2AX

  • Track foci formation kinetics (5 min to 6 hours post-treatment)

Research has shown that RAD52 foci appear in most MEFs within 5 minutes of CPT treatment and persist up to 6 hours post-treatment, indicating rapid binding to damaged DNA .

What are the methodological considerations for studying RAD52's role in single-strand annealing (SSA)?

Studying RAD52's role in SSA requires careful experimental design:

• Cell-based SSA reporter systems:

  • Use U2OS cells with chromosomally integrated SSA-GFP construct containing:

    • 5' fragment of GFP gene

    • 3' fragment of GFP with I-SceI endonuclease site

    • 2.7 kb separation between fragments

  • Transfect cells with I-SceI expressing vector to induce DSB

  • SSA repair restores functional GFP, measurable by flow cytometry

• Genetic manipulation approaches:

  • Generate RAD52 knockout cells using CRISPR-Cas9

  • Create cell lines expressing RAD52 mutants (e.g., YI65-66AA, K102A/K133A) or truncations (RAD52 1-209)

  • Perform rescue experiments by expressing exogenous RAD52 variants in knockout backgrounds

• Controls and measurements:

  • Include wildtype RAD52 as positive control

  • Use RAD52 knockout as negative control

  • Normalize GFP-positive cell percentages to transfection efficiency

• In vitro SSA assays:

  • Purify recombinant RAD52 protein (full-length or domains)

  • Conduct ssDNA annealing assays using complementary oligonucleotides

  • Monitor annealing by gel electrophoresis or fluorescence-based methods

Research has demonstrated that RAD52 knockout reduces SSA efficiency approximately 2-fold, and while RAD52 1-209 expression increases SSA ~1.5-fold compared to knockout cells, the DNA-binding deficient mutants (YI65-66AA and K102A/K133A) fail to rescue the SSA defect .

How can I effectively measure DNA binding and annealing activities of RAD52 in vitro?

To measure RAD52's DNA binding and annealing activities:

• Protein preparation:

  • Express and purify recombinant RAD52 (full-length or domains)

  • Include controls: RAD52 1-209, RAD52 YI65-66AA, and RAD52 K102A/K133A mutants

• ssDNA binding assays:

  • Electrophoretic mobility shift assay (EMSA):

    • Incubate RAD52 with 32P-labeled oligonucleotides

    • Analyze complexes by non-denaturing gel electrophoresis

  • Fluorescence anisotropy:

    • Use fluorescently labeled DNA

    • Measure changes in anisotropy upon protein binding

• ssDNA annealing assays:

  • Gel-based assay:

    • Pre-incubate RAD52 with one labeled oligonucleotide

    • Add complementary strand

    • Analyze annealing products by gel electrophoresis

  • RPA competition:

    • Pre-incubate ssDNA with RPA before adding RAD52

    • Determine if RAD52 can promote annealing of RPA-coated ssDNA

• D-loop formation:

  • Incubate RAD52 with 32P-labeled ssDNA

  • Add homologous supercoiled plasmid dsDNA

  • Analyze D-loop products by gel electrophoresis

• Inverse RNA strand exchange (IRSE) assay:

  • Assemble nucleoprotein complexes by incubating RAD52 with tailed dsDNA

  • Add homologous RNA

  • Analyze products by polyacrylamide gel electrophoresis

Protocol details from published research:

• For IRSE assays: Use 900 nM RAD52 WT, 1.4 μM RAD52 1-209, or 900 nM mutants with 68.6 nM tailed dsDNA in buffer containing 25 mM Tris-acetate pH 7.5, 100 μg/ml BSA, 2 mM magnesium acetate, and 2 mM DTT at 37°C

• Analyze samples by electrophoresis in 10% polyacrylamide gels at 13 V/cm for 1.5 h

How does RAD52 influence PARP-mediated single-strand break repair (SSBR), and how can this be experimentally demonstrated?

RAD52's influence on PARP-mediated SSBR represents a complex area of research:

• Mechanism of influence:

  • RAD52 appears to inhibit PARP-mediated SSBR through its strong ssDNA/PAR binding affinity

  • This inhibition reduces DNA-damage-promoted XRCC1-LIG3α interaction

  • The mechanism appears conserved across vertebrates, as demonstrated in chicken DT40 cells, mouse embryonic fibroblasts (MEFs), and human U2OS cells

• Experimental approach to demonstrate this effect:

  • Cell survival assays:

    • Treat wildtype and RAD52-deficient cells with camptothecin (CPT)

    • Compare survival rates with and without PARP inhibitors (PARPi)

    • Key finding: RAD52-deficient cells show increased resistance to CPT, but this resistance is reversed when combined with PARPi

  • γ-H2AX foci analysis:

    • Quantify γ-H2AX foci (DSB marker) in WT vs. RAD52-deficient cells after CPT treatment

    • Compare with and without PARPi

    • Key finding: RAD52-deficient cells show fewer γ-H2AX foci after CPT alone, but more foci when CPT is combined with PARPi

  • Chromatin-bound protein analysis:

    • Isolate chromatin fractions at different time points after CPT treatment

    • Compare levels of SSBR proteins (PARP1, XRCC1, LIG3α) in WT vs. RAD52-deficient cells

    • Key finding: RAD52-expressing cells show higher chromatin-bound levels of repair proteins

  • XRCC1 foci kinetics:

    • Track XRCC1 foci formation after CPT treatment in control vs. RAD52-knockdown cells

    • Key finding: RAD52 knockdown cells show more XRCC1 foci-positive cells at early time points (5 min) after CPT treatment

Research has revealed that PARP inhibition combined with CPT treatment increases cell sensitivity to CPT in RAD52-deficient cells, suggesting RAD52's inhibitory effects are PARP-dependent .

What techniques should be employed to investigate the synthetic lethality between RAD52 inhibition and BRCA deficiency?

Investigating synthetic lethality between RAD52 inhibition and BRCA deficiency requires sophisticated experimental strategies:

• Cell viability and colony formation assays:

  • Cell models: Use paired cell lines (BRCA-proficient vs. BRCA-deficient):

    • MDA-MB-436 and HCC1937 (BRCA1-/-)

    • CAPAN-1 (BRCA2-/-)

  • RAD52 inhibition methods:

    • shRNA targeting RAD52 3'UTR

    • CRISPR-Cas9 knockout followed by complementation

    • Small molecule RAD52 inhibitors

  • Rescue experiments:

    • Express RAD52 variants (WT, 1-209, YI65-66AA, K102A/K133A)

    • Quantify colony formation after 10-14 days

• Homology-directed repair (HDR) assays:

  • Use DR-GFP reporter system in BRCA-deficient cells

  • Measure GFP-positive cells after I-SceI-induced DSB

  • Compare HDR efficiency with different RAD52 variants

• Mechanistic investigations:

  • Protein interactions:

    • Immunoprecipitation of RAD52 with RAD51, RPA

    • Proximity ligation assays (PLA)

  • DNA damage response:

    • Monitor γH2AX, 53BP1, and RAD51 foci

    • Track cell cycle checkpoints via flow cytometry

• Combinatorial approaches:

  • Combine RAD52 inhibition with PARP inhibitors

  • Test chemotherapeutic agents (platinum compounds)

  • Analyze synergistic effects using combination indexes

Research findings show that RAD52 1-209 alone is sufficient to maintain viability in both BRCA1-/- and BRCA2-/- cells. In MDA-MB-436 cells, RAD52 1-209 rescue was nearly as robust as RAD52 WT, while in HCC1937 cells, the rescue effect was partial (~1.5-fold lower than RAD52 WT). In CAPAN-1 cells (BRCA2-/-), RAD52 1-209 rescue was comparable to RAD52 WT .

How can researchers investigate RAD52's role in resolving transcription-replication conflicts (TRCs) and R-loop metabolism?

To investigate RAD52's role in TRC resolution and R-loop metabolism:

• R-loop detection and quantification:

  • DNA-RNA hybrid immunoprecipitation (DRIP):

    • Use S9.6 antibody that recognizes DNA-RNA hybrids

    • Perform DRIP-qPCR for specific genomic regions

    • Conduct DRIP-seq for genome-wide R-loop mapping

  • S9.6 immunofluorescence:

    • Visualize R-loops in fixed cells

    • Quantify signal intensity before and after RAD52 depletion

    • Use RNase H treatment as specificity control

• RAD52 interactions with transcription machinery:

  • Mass spectrometry analysis:

    • Immunoprecipitate RAD52 from cells under physiological conditions

    • Identify interacting proteins by mass spectrometry

    • Research finding: RAD52 predominantly interacts with transcription complex proteins

  • Co-immunoprecipitation (Co-IP):

    • Validate interactions between endogenous RAD52 and RNA Pol II

    • Test if interactions are DNA/RNA dependent using nuclease treatments

  • Proximity ligation assay (PLA):

    • Visualize RAD52-Pol II interactions in situ

    • Research finding: Clear evidence for RAD52-Pol II interaction independent of DNA or RNA

• Replication stress analysis:

  • DNA fiber assay:

    • Pulse cells with CldU and IdU for 30 minutes each

    • Measure fiber track lengths to assess replication fork progression

    • Research finding: RAD52 depletion led to reduced DNA fiber track lengths, indicating increased replication stress

  • γH2AX ChIP-seq around R-loops:

    • Map DNA damage at R-loop forming regions

    • Compare WT vs. RAD52-depleted cells

    • Research finding: Increased γH2AX accumulation at R-loop forming genes in RAD52-depleted cells

• Domain-specific functions:

  • Express RAD52 truncations or mutations

  • Assess their ability to resolve R-loops and TRCs

  • Research finding: RAD52's C-terminal domain is essential for interaction with Pol II and helps recruit TOP2A to R-loops

Data from these studies revealed that RAD52 depletion increases R-loop accumulation, exacerbates TRCs, and results in elevated DNA damage, particularly at conserved R-loop sites .

What are the critical considerations for validating RAD52 antibody specificity in various experimental systems?

Validating RAD52 antibody specificity is crucial for reliable research outcomes:

• Genetic controls:

  • Generate RAD52 knockout cells using CRISPR-Cas9

  • Create single guide RNAs (sgRNAs) targeting RAD52 exons

  • Verify knockout by PCR and western blot

  • Use knockout cells as negative controls in all antibody-based experiments

• Epitope tagging validation:

  • Express tagged versions (HA, FLAG, etc.) of RAD52 in cells

  • Perform dual immunostaining with anti-RAD52 and anti-tag antibodies

  • Confirm co-localization pattern

  • Research finding: Complete co-localization between RAD52 and HA antibodies confirms antibody specificity

• Multiple antibody comparison:

  • Test antibodies from different suppliers or raised against different epitopes

  • Compare staining patterns, western blot bands, and immunoprecipitation efficiency

  • Antibody options:

    • Monoclonal: RAD52 Antibody (F-7) from Santa Cruz (#sc-365341)

    • Polyclonal: Antibodies recognizing specific regions (N-terminal, middle, C-terminal)

• Cross-reactivity testing:

  • Examine antibody recognition of related proteins (e.g., RAD52B)

  • Test reactivity across species if working with non-human models

  • Verify reactivity with mutant or truncated RAD52 proteins

• Application-specific validation:

  • Western blotting: RAD52 appears at ~46-50 kDa

  • Immunofluorescence: Verify nuclear localization and foci formation patterns

  • ChIP: Include IgG controls and known RAD52 binding sites as positive controls

Technical specifications for common RAD52 antibodies:

How can researchers accurately measure and interpret RAD52 foci dynamics in response to different DNA-damaging agents?

Accurate measurement and interpretation of RAD52 foci dynamics requires:

• Optimized immunostaining protocol:

  • Fixation: 4% paraformaldehyde (10 min at room temperature)

  • Permeabilization: 0.2% Triton X-100 (5 min)

  • Blocking: 3-5% BSA (1 hour)

  • Primary antibody incubation: Anti-RAD52 (overnight at 4°C)

  • Include γH2AX co-staining as DNA damage marker

• Time-course analysis:

  • Establish appropriate time points based on DNA damage type:

    • For camptothecin (CPT): 5 min, 30 min, 1h, 3h, 6h post-treatment

    • For cisplatin: 6h, 12h, 24h post-treatment

    • For ionizing radiation: 0.5h, 2h, 6h, 24h post-exposure

  • Research finding: RAD52 foci appear in most MEFs within 5 min of CPT treatment and persist up to 6h

• Quantification approaches:

  • Manual counting:

    • Count nuclei with ≥5 foci per cell

    • Calculate percentage of foci-positive cells

  • Automated analysis:

    • Use software like CellProfiler, ImageJ with FIJI

    • Apply consistent thresholding parameters

    • Measure intensity, number, and size of foci

• Co-localization analysis:

  • Quantify overlap between RAD52 and other repair proteins

  • Calculate Pearson's or Mander's coefficients

  • Examine spatial relationships with γH2AX, RAD51, BRCA1/2, or RPA

• Control experiments:

  • Include untreated controls

  • Use RAD52 knockout cells as negative controls

  • For overexpressed RAD52, normalize to expression levels

• Data interpretation guidelines:

  • Increased RAD52 foci after DNA damage indicates recruitment to damaged sites

  • Persistent foci may suggest impaired repair

  • RAD52 foci in BRCA-deficient cells indicate alternative repair pathway activation

  • Co-localization with γH2AX confirms association with DNA damage sites

Research has demonstrated that RAD52 forms nuclear foci that co-localize with γH2AX foci after DNA damage, both for full-length RAD52 and the RAD52 1-209 N-terminal domain fragment .

What are the most effective approaches for studying RAD52's DNA/RNA pairing activities in vitro and interpreting contradictory results?

Studying RAD52's DNA/RNA pairing activities and resolving contradictory results requires sophisticated approaches:

• Biochemical assays for DNA/RNA pairing activities:

  • D-loop formation assay:

    • Incubate RAD52 with 32P-labeled ssDNA (e.g., oligo #160)

    • Add homologous supercoiled plasmid dsDNA (e.g., pUC19)

    • Resolve products on 0.9% agarose gels

    • Research finding: RAD52 1-209 shows activity comparable to full-length, while YI65-66AA and K102A/K133A mutants are inactive

  • Inverse RNA strand exchange (IRSE) assay:

    • Form nucleoprotein complexes with RAD52 and 3'-tailed dsDNA

    • Add homologous RNA

    • Analyze by polyacrylamide gel electrophoresis

    • Research finding: RAD52 YI65-66AA is almost completely defective, while K102A/K133A is partially defective compared to WT

  • ssDNA annealing assay:

    • Pre-incubate RAD52 with one oligonucleotide

    • Add complementary strand

    • Monitor annealing by gel electrophoresis

    • Research finding: RAD52 1-209 requires 2-4 fold higher concentration than full-length for optimal activity

• Addressing contradictory results:

  • Protein preparation variables:

    • Compare different purification methods

    • Test for optimal protein:DNA ratios

    • Assess protein activity over time/storage conditions

  • Buffer condition optimization:

    • Systematically vary salt concentration, pH, and divalent cations

    • Test additives like BSA, glycerol, or reducing agents

    • Published optimal buffer: 25 mM Tris-acetate pH 7.5, 100 μg/ml BSA, 2 mM magnesium acetate, 2 mM DTT

  • Substrate variation:

    • Compare different DNA/RNA sequences

    • Test varying lengths of nucleic acids

    • Evaluate impact of secondary structures

• Controls to include:

  • Positive controls: Known active proteins (full-length RAD52)

  • Negative controls: Heat-inactivated protein, buffer-only

  • Domain mutants: YI65-66AA (primary DNA binding site) and K102A/K133A (secondary DNA binding site)

• Interpretation framework for contradictory results:

  • Concentration-dependent effects:

    • RAD52 1-209 requires higher concentrations to compensate for inability to form higher-order structures

  • RPA effects:

    • Pre-incubation with RPA shows differential effects on RAD52 variants

    • RPA marginally inhibits RAD52 1-209 but not full-length protein

  • In vitro vs. in vivo differences:

    • Consider cellular factors not present in purified systems

    • Validate biochemical findings with cell-based assays

When facing contradictory results, systematically vary experimental conditions while maintaining appropriate controls to identify variables affecting RAD52 activity.

How can RAD52 antibodies be used to assess the potential of RAD52-targeting therapies in BRCA-deficient cancers?

RAD52 antibodies play crucial roles in evaluating RAD52-targeting therapies for BRCA-deficient cancers:

• Expression profiling in patient samples:

  • Use immunohistochemistry with RAD52 antibodies on tissue microarrays

  • Quantify expression levels in normal vs. tumor tissues

  • Correlate expression with BRCA mutation status

  • Analyze relationship between RAD52 expression levels and patient outcomes

  • Research finding: Aberrant RAD52 expression is associated with poor cancer prognosis

• Target engagement studies:

  • Evaluate RAD52 inhibitor binding to target:

    • Cellular thermal shift assay (CETSA) with RAD52 antibodies

    • Drug affinity responsive target stability (DARTS)

  • Monitor RAD52 foci formation before and after inhibitor treatment

  • Assess protein-protein interactions (RAD52-RAD51, RAD52-RPA) via co-immunoprecipitation

• Efficacy markers in preclinical models:

  • Cell-based assays:

    • Colony formation in BRCA1-/- cells (MDA-MB-436, HCC1937)

    • Cell viability in BRCA2-/- cells (CAPAN-1)

    • Monitor RAD52 function after inhibitor treatment

  • Patient-derived xenografts (PDXs):

    • Treat PDX models with RAD52 inhibitors

    • Analyze tumor sections for RAD52 expression/localization

    • Correlate with treatment response

• Functional domain targeting validation:

  • Use domain-specific antibodies to determine which RAD52 functions are inhibited

  • Research finding: N-terminal domain (1-209) is essential for maintaining viability in BRCA-deficient cells

  • Focus on compounds that disrupt DNA/RNA pairing rather than RAD51 mediator function

• Combination therapy assessment:

  • Evaluate RAD52 expression/localization after PARP inhibitor treatment

  • Test sequential vs. concurrent administration of RAD52 and PARP inhibitors

  • Research finding: Blocking RAD52 oligomerization while retaining ssDNA binding capacity sensitizes cells to different DNA-damaging agents

These approaches utilizing RAD52 antibodies can help identify patients likely to respond to RAD52-targeting therapies and develop effective treatment strategies for BRCA-deficient cancers.

What techniques should be used to investigate the role of RAD52 in R-loop-associated genomic instability across different cancer types?

Investigating RAD52's role in R-loop-associated genomic instability requires integrative approaches:

• R-loop profiling in cancer specimens:

  • DRIP-seq (DNA-RNA immunoprecipitation sequencing):

    • Map genome-wide R-loop distribution in normal vs. cancer tissues

    • Compare samples with high vs. low RAD52 expression

    • Research finding: Increased mutational burden at conserved R-loop sites in tumors with low RAD52 expression

  • S9.6-RAD52 PLA (proximity ligation assay):

    • Detect in situ association between RAD52 and R-loops

    • Quantify in tissue microarrays across cancer types

    • Research finding: Loss of RAD52 increases S9.6-γH2AX PLA signals, indicating DNA damage at R-loops

• Functional validation in cancer cells:

  • RAD52 depletion/overexpression:

    • Use CRISPR-Cas9 or shRNA to deplete RAD52

    • Analyze R-loop levels by S9.6 immunofluorescence

    • Measure γH2AX at R-loop regions by ChIP-seq

    • Research finding: RAD52 deficiency increases R-loop accumulation and DNA damage

  • Transcription-replication conflict analysis:

    • Perform EdU-EU co-labeling to detect TRCs

    • Measure replication stress via DNA fiber assay

    • Research finding: RAD52 depletion induces elevated levels of Pol II pausing and R-loop accumulation

• Mechanistic investigations:

  • RAD52 interactome in cancer cells:

    • Perform immunoprecipitation-mass spectrometry

    • Identify cancer-specific interaction partners

    • Research finding: RAD52 predominantly interacts with transcription complex proteins

  • Domain-specific functions:

    • Express RAD52 truncations in RAD52-deficient cells

    • Test C-terminal domain in recruiting TOP2A to R-loops

    • Research finding: C-terminal domain of RAD52 is essential for interaction with Pol II and TOP2A recruitment

• Clinical correlations:

  • Analyze cancer genomics databases (TCGA, ICGC)

  • Correlate RAD52 expression with mutation signatures

  • Research finding: Increased mutations at R-loop forming regions in tumors with low RAD52 expression

  • Examine relationship between transcription stress markers and RAD52 expression